摘要
目的探讨帕利哌酮与齐拉西酮对精神分裂症患者认知功能和生活质量的影响。方法采用随机数字表法将符合《国际疾病分类(第10版)》(ICD-10)精神分裂症诊断标准的96例精神分裂症患者分为帕利哌酮缓释片组(观察组)和齐拉西酮胶囊组(对照组)各48例,分别于治疗前和治疗8周后采用威斯康星卡片分类测验(WCST)和持续操作测验(CPT)测评认知功能,采用世界卫生组织生存质量简表(WHOQOL-BREF)测评生活质量。结果治疗8周后观察组WCST中的正确应答数、持续性错误数较对照组改善,差异有统计学意义(t=2.294、2.049,P<0.05)。观察组CPT2及CPT3较对照组改善,差异有统计学意义(t=2.242,P<0.05;t=2.671,P<0.01)。观察组在WHOQOL-BREF的生理领域、心理领域及社会关系领域较对照组改善,差异有统计学意义(t=2.465、2.166、2.444,P<0.05)。结论帕利哌酮缓释片对改善精神分裂症患者的认知功能和生活质量优于齐拉西酮。
Objective To explore the influence of paliperidone and ziprasidone on the cognitive function and quality of life in pa-tients with schizophrenia. Methods 96 cases of schizophrenia patients conform to the International classification of diseases tenth edi-tion（ICD - 10）were randomly divided into paliperidone group（observation group,48 cases）and ziprasidone capsule group（control group,48 cases）by using the random number table method. Two groups of patients were assessed by Wisconsin Card Sorting Test （WCST）,Continuous Performance Test（CPT）to evaluate cognitive function and using WHO Quality of Life - BREF（WHOQOL -BREF）to evaluate quality of life before and after 8 weeks of treatment. Results The scores of the number of correct response and per-sistent error number of WCST in observation group improved was statistically significant than control group after 8 weeks treatment（t =2. 294,t = 2. 049,P 〈 0. 05）. The scores of the CPT2 and CPT3 in observation group improved was statistically significant than control group（t = 2. 242,P 〈 0. 05;t = 2. 671,P 〈 0. 01）. The scores of the field of physiological,psychological and social relationship of WHOQOL - BREF in observation group improved was statistically significant than control group（t = 2. 465,2. 166,2. 444,P 〈 0. 05）. Conclusion Paliperidone extended - release tablet can be effectively to improve the cognitive function and quality of life in patients with schizophrenia was better than ziprasidone.
出处
《四川精神卫生》
2015年第2期134-137,共4页
Sichuan Mental Health
